Abstract
For patients with acute coronary syndrome, lipid-lowering therapy with atorvastatin, 80 mg/d, reduces recurrent ischemic events in the first 16 weeks, mostly recurrent symptomatic ischemia requiring rehospitalization.
Keywords
MedicineAtorvastatinMyocardial infarctionAcute coronary syndromeClinical endpointInternal medicineCardiologyUnstable anginaPlaceboRelative riskRandomized controlled trialAnginaConfidence interval
Affiliated Institutions
Related Publications
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Among patients who have recently had an acute coronary syndrome, an intensive lipid-lowering statin regimen provides greater protection against death or major cardiovascular eve...
High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction<SUBTITLE>The IDEAL Study: A Randomized Controlled Trial</SUBTITLE>
In this study of patients with previous MI, intensive lowering of LDL-C did not result in a significant reduction in the primary outcome of major coronary events, but did reduce...
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
The lowering of cholesterol concentrations in individuals at high risk of cardiovascular disease improves outcome. No study, however, has assessed benefits of cholesterol loweri...
Ability of Minor Elevations of Troponins I and T to Predict Benefit From an Early Invasive Strategy in Patients With Unstable Angina and Non-ST Elevation Myocardial Infarction<SUBTITLE>Results From a Randomized Trial</SUBTITLE>
In patients with clinically documented acute coronary syndrome who are treated with glycoprotein IIb/IIIa inhibitors, even small elevations in cTnI and cTnT identify high-risk p...
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
Intensive lipid-lowering therapy with 80 mg of atorvastatin per day in patients with stable CHD provides significant clinical benefit beyond that afforded by treatment with 10 m...
Publication Info
- Year
- 2001
- Type
- article
- Volume
- 285
- Issue
- 13
- Pages
- 1711-1711
- Citations
- 2464
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
2464
OpenAlex
Cite This
Gregory G. Schwartz
(2001).
Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes<SUBTITLE>The MIRACL Study: A Randomized Controlled Trial</SUBTITLE>.
JAMA
, 285
(13)
, 1711-1711.
https://doi.org/10.1001/jama.285.13.1711
Identifiers
- DOI
- 10.1001/jama.285.13.1711